US · Healthcare · Biotechnology
EPS came in at -0.16 against a street estimate of -0.42 — a beat of 61.9%.
Analysts rate Tarsus Pharmaceuticals Inc a strong buy (7 buy, 1 hold, 0 sell out of 8) with an average price target of $94.22.
| Fund | Stake |
|---|---|
| Deep Track Capital, LP | 8.25% |
| BlackRock Inc | 8.14% |
| RTW INVESTMENTS, LLC | 7.67% |
| Paradigm Biocapital Advisors LP | 5.87% |
| HHG PLC | 5.14% |
| Morgan Stanley - Brokerage Accounts | 4.46% |
| Vanguard Capital Management, LLC | 4.04% |
| Jennison Associates LLC | 3.92% |
| Document | Date |
|---|---|
| Board / officer change · Q3 2026 | 2026-07-13 |
| Material agreement · Q3 2026 | 2026-07-08 |
| Shareholder vote results · Q2 2026 | 2026-06-29 |
| Quarterly report · Q1 2026 | 2026-05-06 |
| Results announced · Q2 2026 | 2026-05-06 |
| Proxy statement · Q2 2026 | 2026-04-28 |
| Annual report FY2025 | 2026-02-23 |
| Quarterly report · Q3 2025 | 2025-11-04 |
Readable in the app.
Technicals, trade setups with a published hit rate, $AI analysis and earnings-call summaries for Tarsus Pharmaceuticals Inc — free to start.
Google PlayApp StoreData updated 2026-08-05.